Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

uPA, uPAR and TGFβ1 Expression during Early and Late Post Myocardial Infarction Period in Rat Myocardium

ANASTASIA STAVROPOULOU, ANASTASSIOS PHILIPPOU, ANTONIOS HALAPAS, ANTIGONE SOURLA, NIKOLAOS PISSIMISSIS and MICHAEL KOUTSILIERIS
In Vivo September 2010, 24 (5) 647-652;
ANASTASIA STAVROPOULOU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANASTASSIOS PHILIPPOU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANTONIOS HALAPAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANTIGONE SOURLA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NIKOLAOS PISSIMISSIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHAEL KOUTSILIERIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mkoutsil@med.uoa.gr
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The expression patterns of transforming growth factor beta 1 (TGFβ1), urokinase-type plasminogen activator (uPA) and uPA receptor (uPAR) were analysed after artery ligation-induced myocardial infarction (MI) in the rat myocardium. uPA and uPAR expressions were significantly increased both at transcriptional and protein level during early phase post MI period (uPA at 1 hour and uPAR at 24 hours post infarction). TGFβ1 mRNA expression profile revealed a significant increase of TGFβ1 expression from day 4 up to 8 weeks post infarction. These data suggest that the need for an increasing TGFβ1 bioavailability during the post-infarction period in rat myocardium is achieved in the early post MI period by an increased expression of uPA/uPAR proteolytic system (indirect activation of latent TGFβ1) and in the late post MI period by direct regulation of TGFβ1 expression. It is therefore concluded that differential regulation of the TGFβ1 bioavailability may be a crucial step of the repair mechanisms during the post MI infarction period in the rat myocardium.

  • TGFβ1
  • uPA
  • uPAR
  • myocardial infarction

Myocardial infarction (MI) induces a process of cardiac muscle regeneration, which includes gross morphological, histological, and molecular changes of both the infracted and residual non-infracted myocardium (1-3). Wound healing is a complex process of invasion, transformation and apoptosis of various cell types which is highly regulated and may well be subject to regulatory influences, disturbances and imbalances (4).

Myocardial extracellular matrix (ECM) mainly consists of collagen, fibronectin and elastin, and forms a three-dimensional network which supports the cellular and structural integrity of the heart. The imbalanced production and degradation of the ECM is an important process for the development of myocardial dysfunction after MI (5). Notably, ECM participates in the regulation of the activity of various growth factors, such as insulin-like growth factors (IGFs) and transforming growth factor beta 1 (TGFβ1), in physiological and pathophysiological processes (6-10). Urokinase-type plasminogen activator (uPA) and plasmin are implicated in several non-fibrinolytic processes, which lead to ECM degradation, either directly by proteolytic cleavage of extracellular matrix components, or indirectly through the activation of matrix metallo-proteinases (MMPs) in several tissues and pathologies (11, 12). However, uPA and MMPs regulate growth factor activities, such as the hydrolysis of the IGF-binding proteins (IGFBPs) and the activation of the latent-TGFβs and other growth substances as noted in various tissues (13-15).

TGFβs are a family of multifunctional growth factors, namely TGFβ1, β2 and β3. A common characteristic of all TGFβs is their ability to bind to extracellular proteins and to be stored in the ECM until activation by a physiological process, such as wound healing (16). In vitro, TGFβs can affect stem cell proliferation and differentiation in a dose-dependent manner, however, it seems that TGFβs can inhibit, induce or have no effect on stem cell proliferation in vivo, depending on whether platelet-derived growth factor (PDGF), fibroblast growth factors (FGFs) or IGFs are present (17). Moreover, it appears that TGFβs have an influence on ECM reorganization throughout the regeneration of myocardium; thus excessive TGFβ-induced deposition of ECM at the site of injury can lead to fibrosis (18).

This study assessed the pattern of the expression levels of uPA, uPAR and TGFβ1, at both mRNA and protein levels, after coronary artery ligation-induced MI during the early and late phases of MI in rat myocardium.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Primer sequences and PCR product sizes.

Materials and Methods

Experimentally induced myocardial infarction in rats. Seventy-two male Wistar rats, weighting 280-330 g, were used in this study. The protocol was approved by the local Ethics Committee. MI was induced according to the procedure previously described (19) and the infarct size was confirmed by the tetrazolium method (19). Briefly, in the anaesthetised rat, the heart was excised and cut from apex to base transversely in 2 mm-thick sections. The sections were then incubated in a 1% solution of triphenyltetrazolium chloride (TTC) for 10 to 15 min until viable myocardium was stained brick red. Infarct-related myocardium fails to be stained with TTC. The tissue sections were then fixed in a 10% formalin solution and weighed. Colour digital images of both sides of each transverse slice were obtained. Based on the observed size of the infarct and on the indicative tissue sections stained with TTC, the infarct zone was measured to be 20-40% as previously published (19). The non-infarct area was collected for use in this study.

RNA extraction and RT-PCR conditions. The rat cardiac tissues were homogenised (Ultra-Turrax T25; Thermo Fisher Scientific, Cheshire, UK) at 15-20,000 rpm and total RNA was extracted according to the Trizol Reagent protocol (Invitrogen Corp, Carlsbad, CA, USA). Diethylpyrocarbonate (DEPC)-treated water was used for the dilution of the RNA pellet. RNA concentration was estimated spectrophotometrically (Genova; Jenway, Essex, UK) by absorbance at 260 nm, and the purity by the ratio of the absorbance at 260/280 nm. RNA integrity was assessed by visualisation of the 18S and 28S ribosomal RNA patterns in a denaturing agarose gel. Two micrograms of total RNA of each sample were reverse-transcribed into cDNA using SuperScript II Reverse Transcriptase (Invitrogen Corp) as described previously (19). In order to study the relative mRNA expression of the TGFβ1, uPA and uPAR in each PCR reaction, each target cDNA was co-amplified with 18S internal standard (Ambion, Austin, TX, USA) and its expression is given as a ratio of the target cDNA/18S. This procedure compensates for differences in the initial amounts of total RNA and in RT efficiency. In order to decrease the 18S signal so as to attain a linear amplification of each target mRNA and 18S to the same range, 18S primers and competimers were mixed at ratios which ranged from 1:2 to 1:4 depending on the abundance of the target mRNA. For both controls and pathological samples of every group, the same premixed reagents were used in order to minimise the differences in PCR efficiency. The relative quantitative RT-PCR method used in the present study has been extensively validated as previously published (20, 21).

Primer sequences for rat TGFβ1 (Accession number: NM0215 78.2), uPA ( accession number: NM01085.3) and uPAR (accession number: BC127499.1) were specifically designed according to the sequences published at NIH (NCBI) and their exact sequence is presented in Table I. Primers were designed using the Primer Select computer program (DNAStar, Madison, WI, USA) and synthesized by Invitrogen Corp. The PCR mix for the amplification was constructed according to the Taq Master Mix Kit protocol (Qiagen, Valencia, CA, USA) and the reactions were carried out in a PTC-200 Peltier Thermal Cycler (MJ Research Inc, Waltham, MA, USA). Annealing temperatures were at 54°C for TGFβ1, at 56°C for uPA and at 57°C for uPAR. Extension temperatures were at 72°C for all the genes. The reaction was accomplished after 35 cycles according to the results of linearity tests for each target mRNA and 18S. The expected sizes of the specific PCR products were initially verified by electrophoretic separation on an 2% agarose gel and all target sequences were identified by sequencing analysis to ensure specificity of the primers and to further verify each target mRNA. In preliminary experiments, each primer set was tested for its compatibility with the 18S primers.

Protein extracts and Western blot analysis. Total proteins were obtained from rat myocardium by lysis of 10 mg of the tissue in 1 ml RIPA Buffer (50 mM Tris-HCl; 150 mM NaCl) containing 0.55 ml Nonidet P-40, protease 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 μg/ml aprotinin, 10 μg/ml leupeptin and phosphatase inhibitors (1 mM sodium ortovanadate, 1 mM NaF); all obtained from Sigma, St. Louis, MO, USA. The samples were homogenised (homogeniser Ultra-Turrax T25; Thermo Fisher Scientific) in the RIPA buffer and then incubated on ice for 20 min. The homogenates were cleared by centrifugation (12.000 rpm, 4°C, 30 min). The extract was stored at −80°C. Protein concentrations were determined by Bio-Rad protein assay (BIO-RAD Laboratories, Hercules, CA, USA).

Equal amounts (50 μg) of protein extracts from the myocardial tissues were used for Western blot analysis under reducing conditions, following the procedure described previously (19). A goat polyclonal antibody (H-140, sc-6831) was used at dilution 1:200 for the detection of uPA and a rabbit polyclonal antibody (FL-290, sc-10815) was at the same dilution for uPAR; all obtained from Santa Cruz Biotechnology, Santa Cruz, CA, USA.

Statistical analysis. Statistical analysis was performed using the Student's t-test. The level of statistical significance was set at p<0.05. All data are presented as mean±standard error of the mean (SEM).

Results

Evaluation of the infarction. In all experimental animals, ligation of the left anterior descending artery provoked an infarct extending from 20% up to 40% of the rat myocardium. Viable myocardium was stained brick red while infarcted myocardium failed to be stained with TTC. In each animal, the infarction was confirmed initially by the cyanotic colour of the injured myocardium and by the deviation of the electrical axis in the electrocardiogram (ECG) as previously published (19).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

mRNA expression of TGFβ1 at different time points after infarction. Bars represent mean values (mean±SEM of 6 measurements) of TGFβ1 mRNA expression, which was normalised to each corresponding ribosomal 18s and expressed as % change over mRNA levels of sham-operated rats (controls).* Statistically significant values: p<0.05.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

mRNA expression of uPA and uPA.R at different time points after infarction. Bars represent mean values (mean±SEM of 6 measurements) of respective mRNA expression, which was normalised to each corresponding ribosomal 18s and expressed as % change over mRNA levels of sham-operated rats (controls).* Statistically significant values: p<0.05.

Pattern of TGFβ1 expression in the post MI period in rat myocardium. The mRNA expression profile of TGFβ1 during the post-infarction period revealed that only after 4 days there was an increase of TGFβ1 expression which lasted up to 8 weeks (Figure 1).

Pattern of uPA/uPAR expression in the post MI period in rat myocardium. The expression pattern of uPA and uPAR during the post-infarction period showed significant increase during the early post MI period (at 1 hour for uPA) and (after 24 hours for uPAR) at both transcriptional and protein levels (Figures 2 and 3).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Expression of uPA and uPA.R at the protein level. Immunoblotting for GAPDH served as a control for protein loading. Expression values (means±SEM of 6 measurments) were normalised to those of corresponding GAPDH in the same immunoblot and expressed as fold of change of the sham-operated rats (controls).* Statistically significant values: p<0.05.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

uPA/TGFβ1/IGFs/IGFBPs bioregulation system in extracellular matrix remodelling during the myocardial repair processes. ECM: Extracellular matrix; IGFs: Insulin-like growth factors; IGFBPs: Insulin-like growth factor binding proteins; MMPs: Matrix metalloproteinases; TGFβs: Transforming growth factors beta; uPA: Urokinase-type plasminogen activator; uPAR: Urokinase-type plasminogen activator receptor.

Discussion

MI is one of the most frequent cardiovascular events in the Western world. Over the last two decades, early mortality after MI has been significantly reduced as a consequence of thrombolytic and antiarhythmic therapies. Consequently, more patients survive the acute phase after MI and enter the wound-healing process that occurs in the days and weeks after MI, which will gradually lead to hypertrophy and heart failure (22-25).

A major mediator in cardiac repair processes is the activation of local growth substances in response to myocardial overload and injury (26). Several studies have demonstrated TGFβ1 as a significant regulator of remodeling processes, because of its anti-inflammatory effects and its involvement in the synthesis of ECM proteins (27-30). The activation of TGFβ is beneficial during the early phase after MI, acting cardioprotectively against ischaemic myocardial damage (31, 32). However, during the late phase of wound-healing processes, its uncontrolled expression leads to heart failure (33). The role of TGFβs in MI is also related to the co-expression and activation of other growth substances, such as IGFs, PDGF and bFGF (17).

Myocardium predominantly consists of myocardial cells and fibroblasts whose main purpose is to synthesise and to regulate the composition of ECM. The predominant presence of fibroblasts in myocardium indicates its dynamic regulation and reveals their significant physiological effects on the overall function of the heart. TGFβ plays a determinant role in the fibroblast proliferation and ECM production, especially of collagen and fibronectin, while reducing degradation of these components (18). Collagen deposition has a dual effect on cardiac structure and function. Increased collagen deposition is an indispensable prerequisite to prevent dilation of the infracted area, although excessive accumulation of collagen in the infracted and non-infarcted myocardium leads to tissue stiffness which results in myocardial dysfunction and ultimately contributes to heart failure (18). Consequently, degradation and synthesis of the ECM should be in balance in order to maintain physiological myocardial function.

The process of ECM degradation during cardiac wound healing is regulated by proteinases, including PAs (34) and MMPs (5). The main mammalian PAs are tissue-type plasminogen activator and uPA. uPA is an extracellular serine protease that binds to its receptor, uPAR, and generates plasmin from plasminogen by cleaving a specific Arg-Val peptide bond located within the protease domain. Plasmin, the active enzyme of the plasminogen/plasmin system, participates in the proteolytic process by degrading a variety of ECM components, thus activating several MMPs and growth substances (35-37). The generation of ECM degradation is tightly controlled by the balance between plasminogen activators and MMP inhibitors (6).

TGFβ1 suppresses the activity of proteases by inducing synthesis of protease inhibitors, such as uPA inhibitor 1 (PAI-1) and tissue inhibitors of metalloproteinases (TIMPs) (6). In addition, the cellular receptor M-6-P/IGF receptor CD222, interacts with uPAR and latent TGFβ1 complex, and active TGFβ1 is released promoting PAI-1 up-regulation which will act as a negative feedback loop to terminate TGFβ1 activation (Figure 4).

Impaired inhibition of wound healing after myocardial infarction and completed protection against cardiac failure was demonstrated in uPA-deficient (10) and plasmin-deficient mice (38); facts that imply a significant role of the uPA-mediated plasminogen-plasmin system in myocardial wound healing process after myocardial infarction. Thus, it is intriguing to elucidate the expression of uPA/uPAR and TGFβ1 system at the transcriptional and translational levels after MI.

The data of the present study supported such a role for TGFβ1 activity during the early post-infarction period of rat myocardium. However, this increase of TGFβ1 activity was not mediated by the induction of TGFβ1 transcription. Apparently, the post-injury tissue needs the increased TGFβ1 bioavailability both in the early and late post MI periods. In the early post MI period (1hour up to 4 days), this task is served mainly by an increased uPA/uPAR expression system, which in its turn, activates latent TGFβ1 already present in ECM of myocardium. Interestingly, based on previous data (19) during this early post MI period, there is also an increase of the transcriptional activity of IGF-1, mainly its MGF isoform, which produces a selective MGF-E peptide. This is important because MGF is known to regulate the recruitment of stem cells in injured muscles (39-41). Indeed, TGFβs can inhibit, induce or have no effect on stem cell proliferation in vivo, depending on whether PDGF, bFGF or IGFs are present (39). In contrast, in the late post MI infarction period there was direct up-regulation of TGFβ1 expression at the transcription level 4 and 8 weeks post MI which corresponds with the time of IGF-1 maximal activity (isoforms IGF-1Ea and MGF) in this model (19). Conceivably, the possible need of synergistic actions between TGFβ1 and IGF-1 or MGF in the early and late stage post MI periods is differentially achieved by an increase of the transcription of IGF-1/MGF and TGFβ1 genes and/or by the activation of stocks of inactive IGF-1 and TGFβ1 in the ECM (latent TGFβ1 and IGFBP-bound IGF-1). Therefore, this differential mode of activation of IGF-1 and TGFβ1 biavailability suggests that different molecular events are taking place during the early and late post MI periods in the rat myocardium.

  • Received May 6, 2010.
  • Revision received May 10, 2010.
  • Accepted May 21, 2010.
  • Copyright © 2010 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Fedak PW,
    2. Verma S,
    3. Weisel RD,
    4. Skrtic M,
    5. Li RK
    : Cardiac remodeling and failure: from molecules to man (Part III). Cardiovasc Pathol 14: 109-119, 2005.
    OpenUrlCrossRefPubMed
    1. Fedak PW,
    2. Verma S,
    3. Weisel RD,
    4. Li RK
    : Cardiac remodeling and failure From molecules to man (Part II). Cardiovasc Pathol 14: 49-60, 2005.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Fedak PW,
    2. Verma S,
    3. Weisel RD,
    4. Li RK
    : Cardiac remodeling and failure: from molecules to man (Part I). Cardiovasc Pathol 14: 1-11, 2005.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Cleutjens JP,
    2. Blankesteijn WM,
    3. Daemen MJ,
    4. Smits JF
    : The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc Res 44: 232-241, 1999.
    OpenUrlFREE Full Text
  4. ↵
    1. Cleutjens JP,
    2. Kandala JC,
    3. Guarda E,
    4. Guntaka RV,
    5. Weber KT
    : Regulation of collagen degradation in the rat myocardium after infarction? J Mol Cell Cardiol 27: 1281-1292, 1995.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Verrecchia F,
    2. Chu ML,
    3. Mauviel A
    : Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem 276: 17058-17062, 2001.
    OpenUrlAbstract/FREE Full Text
    1. Godar S,
    2. Horejsi V,
    3. Weidle UH,
    4. Binder BR,
    5. Hansmann C,
    6. Stockinger H
    : M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-beta1. Eur J Immunol 29: 1004-1013, 1999.
    OpenUrlCrossRefPubMed
    1. Leksa V,
    2. Godar S,
    3. Cebecauer M,
    4. Hilgert I,
    5. Breuss J,
    6. Weidle UH,
    7. Horejsi V,
    8. Binder BR,
    9. Stockinger H
    : The N terminus of mannose 6-phosphate/insulin-like growth factor 2 receptor in regulation of fibrinolysis and cell migration. J Biol Chem 277: 40575-40582, 2002.
    OpenUrlAbstract/FREE Full Text
    1. Leksa V,
    2. Godar S,
    3. Schiller HB,
    4. Fuertbauer E,
    5. Muhammad A,
    6. Slezakova K,
    7. Horejsi V,
    8. Steinlein P,
    9. Weidle UH,
    10. Binder BR,
    11. Stockinger H
    : TGF-beta-induced apoptosis in endothelial cells mediated by M6P/IGFII-R and mini-plasminogen. J Cell Sci 118: 4577-4586, 2005.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Heymans S,
    2. Luttun A,
    3. Nuyens D,
    4. Theilmeier G,
    5. Creemers E,
    6. Moons L,
    7. Dyspersin GD,
    8. Cleutjens JP,
    9. Shipley M,
    10. Angellilo A,
    11. Levi M,
    12. Nube O,
    13. Baker A,
    14. Keshet E,
    15. Lupu F,
    16. Herbert JM,
    17. Smits JF,
    18. Shapiro SD,
    19. Baes M,
    20. Borgers M,
    21. Collen D,
    22. Daemen MJ,
    23. Carmeliet P
    : Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 5: 1135-1142, 1999.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Irigoyen JP,
    2. Munoz-Canoves P,
    3. Montero L,
    4. Koziczak M,
    5. Nagamine Y
    : The plasminogen activator system: biology and regulation. Cell Mol Life Sci 56: 104-132, 1999.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Stepanova VV,
    2. Tkachuk VA
    : Urokinase as a multidomain protein and polyfunctional cell regulator. Biochemistry (Mosc) 67: 109-118, 2002.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Rifkin DB,
    2. Mazzieri R,
    3. Munger JS,
    4. Noguera I,
    5. Sung J
    : Proteolytic control of growth factor availability. APMIS 107: 80-85, 1999.
    OpenUrlCrossRefPubMed
    1. Bogdanos J,
    2. Karamanolakis D,
    3. Tenta R,
    4. Tsintavis A,
    5. Milathianakis C,
    6. Mitsiades C,
    7. Koutsilieris M
    : Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. Endocr Relat Cancer 10: 279-289, 2003.
    OpenUrlAbstract
  10. ↵
    1. Koutsilieris M,
    2. Mitsiades C,
    3. Sourla A
    : Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer. Mol Med 6: 251-267, 2000.
    OpenUrlPubMed
  11. ↵
    1. Hyytiainen M,
    2. Penttinen C,
    3. Keski-Oja J
    : Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin Lab Sci 41: 233-264, 2004.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Robertson TA,
    2. Maley MA,
    3. Grounds MD,
    4. Papadimitriou JM
    : The role of macrophages in skeletal muscle regeneration with particular reference to chemotaxis. Exp Cell Res 207: 321-331, 1993.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Border WA,
    2. Noble NA
    : Transforming growth factor beta in tissue fibrosis. N Engl J Med 331: 1286-1292, 1994.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Stavropoulou A,
    2. Halapas A,
    3. Sourla A,
    4. Philippou A,
    5. Papageorgiou E,
    6. Papalois A,
    7. Koutsilieris M
    : IGF-1 expression in infarcted myocardium and MGF-E peptide actions in rat cardiomyocytes in vitro. Mol Med 15: 127-135, 2009.
    OpenUrlPubMed
  15. ↵
    1. Bickel CS,
    2. Slade JM,
    3. Haddad F,
    4. Adams GR,
    5. Dudley GA
    : Acute molecular responses of skeletal muscle to resistance exercise in able-bodied and spinal cord-injured subjects. J Appl Physiol 94: 2255-2262, 2003.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Kim JS,
    2. Cross JM,
    3. Bamman MM
    : Impact of resistance loading on myostatin expression and cell cycle regulation in young and older men and women. Am J Physiol Endocrinol Metab 288: E1110-1119, 2005.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. McKee PA,
    2. Castelli WP,
    3. McNamara PM,
    4. Kannel WB
    : The natural history of congestive heart failure: the Framingham study. N Engl J Med 285: 1441-1446, 1971.
    OpenUrlCrossRefPubMed
    1. Lloyd-Jones DM,
    2. Larson MG,
    3. Leip EP,
    4. Beiser A,
    5. D'Agostino RB,
    6. Kannel WB,
    7. Murabito JM,
    8. Vasan RS,
    9. Benjamin EJ,
    10. Levy D
    : Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106: 3068-3072, 2002.
    OpenUrlAbstract/FREE Full Text
    1. Ju H,
    2. Zhao S,
    3. Tappia PS,
    4. Panagia V,
    5. Dixon IM
    : Expression of Gq alpha and PLC-beta in scar and border tissue in heart failure due to myocardial infarction. Circulation 97: 892-899, 1998.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Sutton MG,
    2. Sharpe N
    : Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101: 2981-2988, 2000.
    OpenUrlFREE Full Text
  19. ↵
    1. Chen D,
    2. Assad-Kottner C,
    3. Orrego C,
    4. Torre-Amione G
    : Cytokines and acute heart failure. Crit Care Med 36: S9-16, 2008.
    OpenUrlPubMed
  20. ↵
    1. Roberts AB
    : Molecular and cell biology of TGF-beta. Miner Electrolyte Metab 24: 111-119, 1998.
    OpenUrlCrossRefPubMed
    1. Massague J,
    2. Chen YG
    : Controlling TGF-beta signaling. Genes Dev 14: 627-644, 2000.
    OpenUrlFREE Full Text
    1. Verrecchia F,
    2. Mauviel A
    : Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 118: 211-215, 2002.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Danielpour D,
    2. Song K
    : Cross-talk between IGF-I and TGF-beta signaling pathways. Cytokine Growth Factor Rev 17: 59-74, 2006.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Grainger DJ
    : Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 24: 399-404, 2004.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Lefer AM,
    2. Tsao P,
    3. Aoki N,
    4. Palladino MA Jr..
    : Mediation of cardioprotection by transforming growth factor-beta. Science 249: 61-64, 1990.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Schultz Jel J,
    2. Witt SA,
    3. Glascock BJ,
    4. Nieman ML,
    5. Reiser PJ,
    6. Nix SL,
    7. Kimball TR,
    8. Doetschman T
    : TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 109: 787-796, 2002.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Ragno P,
    2. Montuori N,
    3. Vassalli JD,
    4. Rossi G
    : Processing of complex between urokinase and its type-2 inhibitor on the cell surface. A possible regulatory mechanism of urokinase activity. FEBS Lett 323: 279-284, 1993.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Carmeliet P,
    2. Moons L,
    3. Lijnen R,
    4. Baes M,
    5. Lemaitre V,
    6. Tipping P,
    7. Drew A,
    8. Eeckhout Y,
    9. Shapiro S,
    10. Lupu F,
    11. Collen D
    : Urokinase-generated plasmin activates matrix metallo-proteinases during aneurysm formation. Nat Genet 17: 439-444, 1997.
    OpenUrlCrossRefPubMed
    1. Suelves M,
    2. Lopez-Alemany R,
    3. Lluis F,
    4. Aniorte G,
    5. Serrano E,
    6. Parra M,
    7. Carmeliet P,
    8. Munoz-Canoves P
    : Plasmin activity is required for myogenesis in vitro and skeletal muscle regeneration in vivo. Blood 99: 2835-2844, 2002.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Kherif S,
    2. Lafuma C,
    3. Dehaupas M,
    4. Lachkar S,
    5. Fournier JG,
    6. Verdiere-Sahuque M,
    7. Fardeau M,
    8. Alameddine HS
    : Expression of matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: a study in experimentally injured and mdx muscles. Dev Biol 205: 158-170, 1999.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Creemers E,
    2. Cleutjens J,
    3. Smits J,
    4. Heymans S,
    5. Moons L,
    6. Collen D,
    7. Daemen M,
    8. Carmeliet P
    : Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am J Pathol 156: 1865-1873, 2000.
    OpenUrlPubMed
  29. ↵
    1. Ng F,
    2. Boucher S,
    3. Koh S,
    4. Sastry KS,
    5. Chase L,
    6. Lakshmipathy U,
    7. Choong C,
    8. Yang Z,
    9. Vemuri MC,
    10. Rao MS,
    11. Tanavde V
    : PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 112: 295-307, 2008.
    OpenUrlAbstract/FREE Full Text
    1. Hill M,
    2. Wernig A,
    3. Goldspink G
    : Muscle satellite (stem) cell activation during local tissue injury and repair. J Anat 203: 89-99, 2003.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Philippou A,
    2. Maridaki M,
    3. Halapas A,
    4. Koutsilieris M
    : The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo 21: 45-54, 2007.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

In Vivo: 24 (5)
In Vivo
Vol. 24, Issue 5
September-October 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
uPA, uPAR and TGFβ1 Expression during Early and Late Post Myocardial Infarction Period in Rat Myocardium
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
5 + 14 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
uPA, uPAR and TGFβ1 Expression during Early and Late Post Myocardial Infarction Period in Rat Myocardium
ANASTASIA STAVROPOULOU, ANASTASSIOS PHILIPPOU, ANTONIOS HALAPAS, ANTIGONE SOURLA, NIKOLAOS PISSIMISSIS, MICHAEL KOUTSILIERIS
In Vivo Sep 2010, 24 (5) 647-652;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
uPA, uPAR and TGFβ1 Expression during Early and Late Post Myocardial Infarction Period in Rat Myocardium
ANASTASIA STAVROPOULOU, ANASTASSIOS PHILIPPOU, ANTONIOS HALAPAS, ANTIGONE SOURLA, NIKOLAOS PISSIMISSIS, MICHAEL KOUTSILIERIS
In Vivo Sep 2010, 24 (5) 647-652;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • IGF1Ec Expression in MG-63 Human Osteoblast-like Osteosarcoma Cells
  • Google Scholar

More in this TOC Section

  • Learning Needle Placement in Soft Tissue With Robot-assisted Navigation
  • Changes in Lactate-related Fecal Microbiome in Hyperlactatemia Diabetic Dogs
  • Effects of Irradiation by Carbon Dioxide Laser Equipped With a Water Spray Function on Bone Formation in Rat Tibiae
Show more Experimental Studies

Similar Articles

In Vivo

© 2023 In Vivo

Powered by HighWire